SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Novo Nordisk A/S (NYSE:NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema.
Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm’s attorneys.
Class Period: Nov. 2, 2022 – Dec. 19, 2024
Lead Plaintiff Deadline: Mar. 25, 2025
Visit: www.hbsslaw.com/investor-fraud/nvo
Contact the Firm Now: NVO@hbsslaw.com | 844-916-0895
Novo Nordisk A/S (NVO) Securities Class Action:
The suit, filed in the U.S. District Court for the District of New Jersey and captioned Moon v. Novo Nordisk A/S, No. 25-cv-00713, accuses the company and certain top executives of securities violations related to disclosures about the drug’s Phase 3 trial, dubbed REDEFINE-1.
The plaintiffs, representing investors who purchased Novo Nordisk securities between Nov. 2, 2022, and Dec. 19, 2024, claim the company misrepresented the likelihood of CagriSema achieving at least 25% …
